TLC-2716 not checked

OrsoBio, Inc

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Hypertriglyceridemia, Nonalcoholic Fatty Liver Disease
Main trialPhase 2
“This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.”In the company’s words, NCT06564584 on ClinicalTrials.gov

Other drugs for Hypertriglyceridemia

All 14 drugs for Hypertriglyceridemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Unknown Jun 2025 Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
Phase 1Completed 13 Apr 2023 A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow TLC-2716

Following is part of Solo: you see every change to TLC-2716 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in